药品信息: FAZACLO®(氯氮平),非典型抗精神病药物,FAZACLO可作为黄色,口服崩解12.5毫克,25毫克,100毫克,150毫克和200毫克的口服给药的不含水的片剂。 FAZACLO片可咀嚼。
每个口服崩解片剂含有氯氮平相当于12.5毫克,25毫克,100毫克,150毫克和200毫克。
FAZACLO的活性组分是氯氮平。其余组分是丙烯酸氨基烷基酯共聚物E,甘露糖醇,阿斯巴甜,微晶纤维素*,硅化微晶纤维素**,交聚维酮,天然和人造的薄荷香料,碳酸氢钠,柠檬酸,三氧化二铁(黄色),和硬脂酸镁
本产品含有阿斯巴甜不适合使用的婴儿。苯酮尿症:含有苯丙氨酸[见警告和注意事项。苯丙氨酸是阿斯巴甜的成分。每12.5毫克,口服崩解片剂含有1.6毫克的阿司帕坦,从而,0.87毫克苯丙氨酸。每25毫克,口服崩解片剂含有3.1毫克的阿司帕坦,从而,1.74毫克苯丙氨酸。每100毫克,口服崩解片含12.4毫克的阿司帕坦,从而,6.96毫克苯丙氨酸。每150毫克,口服崩解片含18.6毫克天冬甜素,因而,10.44毫克苯丙氨酸。每次200毫克,口服崩解片含24.8毫克阿斯巴甜,因此,13.92毫克的苯丙氨酸。可允许的每日摄入量的阿斯巴甜是每千克体重每天50毫克。
不良反应
1、镇静作用强和抗胆碱能不良反应较多,常见有头晕、无力、嗜睡、多汗、流涎、恶心、呕吐、口干、便秘、体位性低血压、心动过速。
2,常见食欲增加和体重增加。
3,可引起心电图异常改变,可引起脑电图改变或癫痫发作。
4,也可引起血糖增高。
5,严重不良反应为粒细胞缺乏症及继发性感染。
6,可引起尿失禁或中枢系统紊乱,临床上应该慎用或不用。
点适应症
本品不仅对精神病阳性症状有效,对阴性症状也有一定效果。适用于急性与慢性精神分裂症的各个亚型,对幻觉妄想型、青春型效果好。也可以减轻与精神分裂症有关的情感症状(如:抑郁、负罪感、焦虑)。对一些用传统抗精神病药治疗无效或疗效不好的病人,改用本品可能有效。本品也用于治疗躁狂症或其他精神病性障碍的兴奋躁动和幻觉妄想。因导致粒细胞减少症,一般不宜作为首选药。
FAZACLO® (clozapine), atypical antipsychotics, FAZACLO as yellow, orally disintegrating 12.5 mg, 25 mg, 100 mg, 150 mg and 200 mg for oral administration, tablets containing no water. FAZACLO chewable tablets.
Each orally disintegrating tablets containing the equivalent of 12.5 mg of clozapine, 25 mg, 100 mg, 150 mg and 200 mg.
Active ingredient FAZACLO is clozapine. The rest component is aminoalkyl methacrylate copolymer E, mannitol, aspartame, microcrystalline cellulose, *, ** silicified microcrystalline cellulose, crospovidone, natural and artificial peppermint flavor, bicarbonate sodium citrate, iron oxide (yellow), and magnesium stearate
This product contains aspartame is not suitable for infants. Phenylketonuria: contains phenylalanine [see Warnings and Precautions. Phenylalanine is aspartame ingredient. Each 12.5 mg, orally disintegrating tablet contains 1.6 mg of aspartame, thus, 0.87 mg of phenylalanine. Each 25 mg orally disintegrating tablet contains 3.1 mg of aspartame, thus, 1.74 mg of phenylalanine. Each 100 mg orally disintegrating tablet contains 12.4 mg of aspartame, thus, 6.96 mg of phenylalanine. Each 150 mg, orally disintegrating tablets containing 18.6 mg of aspartame, and thus, 10.44 mg of phenylalanine. Each 200 mg, orally disintegrating tablet contains 24.8 milligrams of aspartame, therefore, 13.92 mg of phenylalanine. The allowable daily intake of aspartame is 50 mg per kilogram of body weight per day.
Adverse reactions
1, strong sedation and anticholinergic adverse reactions are more common with dizziness, weakness, drowsiness, sweating, salivation, nausea, vomiting, dry mouth, constipation, orthostatic hypotension, tachycardia.
2. Common increased appetite and weight gain.
3, can cause abnormal ECG changes can cause EEG changes or seizures.
4, may also cause hyperglycemia.
5, serious adverse reactions and agranulocytosis secondary infections.
6, can cause incontinence or central nervous system disorders, clinically should be used with caution or not.
Indications point
This product is not only effective for positive symptoms of psychosis, negative symptoms also have some effect. Applicable to all subtypes of acute and chronic schizophrenia, paranoid hallucinations, youth-type effects. You can also alleviate affective symptoms associated with schizophrenia (such as: depression, guilt, anxiety). Some of the bad effect of therapy or patients with conventional antipsychotics, change the FDA may be effective. This product is also used to treat mania or other psychotic disorders agitation and hallucinations delusions. Due cause neutropenia, generally should not be used as the drug of choice. |